INTRODUCTION

Study design
Repeated dose toxicity studies DEHA was dissolved in corn oil, and orally administered to rats by gavage at the doses of 0, 200, 1,000 and 2,000 mg/kg for 2 weeks or 4 weeks from 6 weeks of age. A vehicle control group was orally administered by gavage with corn oil. All groups consisted of 10 animals each. The same doses as female fertility study were selected. Each animal received the test or control article at a volume-dosage of 5 ml/kg, using a stomach tube for rats (Fuchigami Kikai, Kyoto, Japan) connected with a disposable injection syringe (Terumo Corporation, Tokyo, Japan).
Females were daily observed for clinical signs, and body weight and food consumption were measured twice a week. Estrous cycles were determined everyday by vaginal smear for 2 weeks before the necropsy. At the day of necropsy, females were euthanized by exsanguination by abdominal aorta dissection under diethylether inhalation anesthesia (Wako Pure Chemical Industries, Ltd.). Ovaries, uterus, vagina, liver, kidneys, adrenals and pituiformalin (Wako Pure Chemical Industries, Ltd.). Ovaries were transversally halved at dissection to observe maximum area of the ovary, embedded in paraffin, and stained with hematoxylin-eosin (HE; Muto Pure Chemicals Co., Ltd., Osaka, Japan) and anti-Proliferation Cell Nuclear Antigen (anti-PCNA) antibody (DAKO Japan Co., Ltd., Kyoto, Japan) for immunohistochemisstained with HE according to the routine procedure. The prepared histopathological specimens were examined under a light microscope.
Female fertility study
DEHA was dissolved in corn oil, and orally administered to rats by gavage at the doses of 0, 200, 1,000 and 2,000 mg/kg for 2 weeks before mating, throughout mating and until 7 day of gestation (Gestation Days 7) from 10 weeks of age. A vehicle control group was orally administered by gavage with corn oil. Dosing method and condition was same as repeated dose toxicity study. All groups consisted of 10 animals each. The doses were selected on the basis of previous report (Miyata et al., 2006) . In the previous report, DEHA was orally administered to Crj:CD(SD) female rats at the doses of 0, 40, 200 and 1,000 mg/kg for 28 days from 8 weeks of age, and disturbance of the estrous cycle and increased ovarian follicle atresia were detected in the 1,000 mg/kg group. From these findings, in the present study, 2,000 mg/kg was selected as the high dose, at which enough effects on fertility was anticipated, 1,000 mg/kg was selected as the middle dose, and 200 mg/kg was selected as the low dose, at which no effects on fertility was anticipated.
After the scheduled 2 weeks treatment periods, females were paired on a 1:1 basis with untreated males. Duration of mating periods was set at 28 days at maximum. Each morning following pairing, the trays beneath the cages were checked for ejected copulation plugs and a vaginal smear was prepared from each female and examined for the presence of sperm. The day on which evidence of copulation was found was designated Gestation Days 0. Number of days till copulation after mating, copulation index (%) ((Number of animals copulated / Number of animals mated) x 100) and fertility index (%) ((Number of pregnant animals / Number of animals copulated) x 100) were calculated.
Females were daily observed for clinical signs, and body weight and food consumption were measured twice a week during 2 weeks before mating and during mating period, daily on Gestation Days 0-8, 11 and 14. Estrous cycles were determined everyday by vaginal smear for 2 weeks before mating and mean estrus cycle length and number of estrus were calculated. Females were euthanized by exsanguination by abdominal aorta dissection under diethylether inhalation anesthesia (Wako Pure Chemical Industries, Ltd.) on Gestation Days 14. After confirmation the presence of pregnancy, the thoracic and intraperitoneal organs were macroscopically examined. In the pregnant females, number of corpora lutea and number of implantations were counted, and implantation rate (%) ((Number of implantations / Number of corpora lutea) x 100) was calculated. Furthermore, number of post-implantation losses and number of live embryos were counted for each dam, and pre-implantation loss rate (%) (([Number of corpora lutea -Number of implantations] / Number of corpora lutea) x 100) and post-implantation loss rate (%) ((Number of post-implantation losses / Number of implantations) x 100) were calculated.
Statistical analysis
For body weight, body weight gain, food consumption, organ weight, mean estrus cycle length, number of estrus, number of days till copulation after mating, number of corpora lutea, number of implantations, number of postimplantation losses and number of live embryos, the mean and standard deviation were calculated in each group. A multiple comparison test was performed between the control group and treated group. That is, homogeneity of variance was tested by Bartlett's test and, if homogenei--For implantation rate, pre-implantation loss rate and postimplantation loss rate, a wilcoxon rank sum test was performed. For copulation index and fertility index, a chiat less than 5%.
RESULTS
Repeated dose toxicity studies
There were no death animals in both 2 weeks and 4 weeks study. In the clinical signs observation, staining around perineum was observed in the 2,000 mg/kg group of the 2 weeks study, and in the 1,000 mg/kg and above groups of the 4 weeks study. In the body weight measurein the 2,000 mg/kg group of 4 weeks study compared with the control group. In the food consumption measurement, there were no abnormal changes in both 2 weeks and 4 weeks study. (Tables 1 and 2) in mean estrous cycle length was observed in the 200 mg/kg group of 2 weeks study compared with the control group, however this change was considered not to be affected by DEHA treatment since there was no dosedependency in this change. No statistically significant changes were observed in the number of estrous in both 2 weeks and 4 weeks study. However some females with abnormal estrous cycle were observed in the 2,000 mg/kg group of the 2 weeks study, and in the 1,000 mg/kg and above groups of the 4 weeks study. (Tables 1 and 2) In the macroscopy, there were no abnormal changes in both 2 weeks and 4 weeks study. In the relative liver in the 1,000 mg/kg and above groups of both 2 weeks and 4 weeks study compared with the control group. In the relative kidneys weight measurement, a significant increase was observed in the 2,000 mg/kg groups of the 2 weeks study, and in the 200 mg/kg and above groups of the 4 weeks study compared with the control group. decrease was observed in the 2,000 mg/kg of the 2 weeks study compared with the control group. (Tables 3 and 4) In the histopathology, abnormal findings were Final food consumption (g) 15 ± 2 15 ± 3 14 ± 3 16 ± 2
Mean estrous cycle length (day) 4.2 ± 0.4 6.9 ± 4.1 4.6 ± 0.4 4.9 ± 0.6 a : Mean ± S.D. Mean estrous cycle length (day) 4.9 ± 0.5 4.1 ± 0.2* 5.0 ± 0.8 5.9 ± 1.9
a : Mean ± S.D.
Vol. 34 Special Issue I SP103 observed in the ovary and kidney in both 2 weeks and 4 weeks study. In the ovary, increase in atresia of large follicle was observed in the 1,000 mg/kg and above groups of both 2 weeks and 4 weeks study with dose-and duration-dependent manner. The maturing stage of this large follicle was from Type 5b to Type 8 (Pedersen's classi--lar cyst was observed in the 2,000 mg/kg group of the 2 weeks study, and in the 1,000 mg/kg and above groups of the 4 weeks study. Decrease in currently formed corpus luteum that was slightly stained with anti-PCNA antibody was observed in the 1,000 mg/kg and above groups of both 2 weeks and 4 weeks study, and there was a lack of currently formed corpus luteum as to the marked -nant pattern at estrous cycle observation had the similar ovarian changes in the 200 mg/kg group of 2 weeks study. In the kidney, eosinophilic change of proximal tubule was observed in the 2,000 mg/kg group of the 2 weeks study, and in the 1,000 mg/kg and above groups of the 4 weeks study. (Fig. 1 , Tables 5 and 6)
Female fertility study
There were no death animals. In clinical signs observation, staining around perineum was observed in the 1,000 mg/kg and above groups. In body weight measurement, a significant decrease in body weight and body weight gain before mating period was observed in the 2,000 mg/ kg group compared with the control group. In food consumption measurement, there were no abnormal changes. (Table 7) In the effects on reproductive functions of dams, a sig- : Increase in atresia of large follicle in ovary treated DEHA 2,000 mg/kg. The large follicles were considered to be atretic since the granulosa cells of large follicles were not stained with anti-PCNA antibody. On the other hand small and medium follicles were normal. (C): Decrease in currently formed corpus luteum in ovary treated DEHA 2,000 mg/kg. It was considered that this animal failed to ovulate for a while, since corpus lutea observed in this animal were previously formed and there were no currently formed corpus lutea that were slightly stained with anti-PCNA antibody. (D): Follicular cyst in ovary treated DEHA 2,000 mg/kg. The antral space was expanded and the granulosa -tion. Scale bar = 500 μm decrease in implantation rate was observed in the 2,000 mg/kg group compared with the control group. No treatment-related abnormalities in number of estrus, number of days till copulation after mating, copulation index and fertility index were observed. (Table 7) In the effects on early embryonic development, a significant increase in post-implantation loss rate was No. of animals examined 10 10 10 10 
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observed in the 1,000 mg/kg and above groups, and a sig--icant increase in pre-implantation loss rate were observed in the 2,000 mg/kg group compared with the control group. (Table 7) DISCUSSION It remains unclear whether the effects on female fertility can be evaluated adequately in a current repeated dose toxicity study since a valid method for evaluating the effects of the drugs on the ovaries has been not established. However, recent advances in the technology for histopathological examination of the ovaries have made more detailed evaluation of the effects of the drugs on the ovaries possible.
DEHA is widely used as a plasticizer in extensive array products, and has been reported that disturbance of the estrous cycle and increased ovarian follicle atresia were observed in the 1,000 mg/kg group (Miyata et al., 2006) . DEHA was orally administered to Crl:CD(SD) female rats at the doses of 0, 200, 1,000 and 2,000 mg/kg for 2 weeks Day 7 of gestation 21 ± 3 22 ± 2 22 ± 3 24 ± 3* Mean estrous cycle length (day) 4.6 ± 1.7 4.2 ± 0.3 4.8 ± 0.5* 5.4 ± 1.1** No. of estrus 3.3 ± 1.2 4.0 ± 0.8 4.3 ± 1.3 4.6 ± 1.8
No. of days till copulation after mating (day) 2.9 ± 2.6 3.6 ± 3.1 3.8 ± 3.7 3.3 ± 3.5
No. of animals mated 10 10 10 10
No. of animals copulated 10 10 10 10
No. of pregnant animals 10 10 10 8
Copulation index (%) 100.0 100.0 100.0 100.0 or 4 weeks in the repeated dose toxicity study and for 2 weeks before mating, throughout mating and until Gesor not the ovarian toxicity could be evaluated by incorporating the new method of histopathological examination of the ovaries into the conventional repeated dose toxici--toxicity study would be correlated with the results of the female fertility study. In the repeated dose toxicity studies, increase in atresia of large follicle, decrease in currently formed corpus luteum and follicular cyst were detected in the ovary as DEHA treatment related changes, because the incidence and severity of these changes increased or intensified with time in the 4 weeks study. Di(2-ethylhexyl) phthalate (DEHP), which is a plasticizer with a structure similar to DEHA, has been reported to inhibit aromatase and suppress estradiol biosynthesis through peroxisome proliferator-activated receptor (PPAR) activation (Davis et al., 1994) . In addition, estradiol is known to suppress apoptosis of the granulosa cells, inhibit alteration to atresia and serve as a hormone indispensable for the maturation of large follicles (Quirk et al., 2006) . Since DEHA possesses PPAR activity, it was considered to be possible that increase in atresia of large follicle by DEHA may also be caused by the inhibition of estradiol biosynthesis and follicular maturation via a similar mechanism of DEHP (Motojima et al., 1998) . Small and medium follicles were normal, suggesting that there -observed in some females treated with DEHA that were judged estrus at estrus cycle observation, suggesting that DEHA disturbed ovulation, to trigger the onset of follicular cyst and a marked decrease in currently formed corpus luteum. Considering the report that DEHP reduces estradiol synthesis, leading to discontinuation of induction of the luteinizing hormone (LH) surge and disturbance of ovulation (Davis et al., 1994) , it was considered to be possible that DEHA may also induce disturbance of decrease in relative ovaries weight observed in the 2,000 mg/kg group was considered attributable to the decrease in newly formed corpus luteum. From these results, the No Observed Adverse Effect Level (NOAEL) focused on the ovary for the repeated dose toxicity study was considered to be 200 mg/kg in both 2 weeks and 4 weeks study.
liver and kidneys weights, and histopathologically eosinophilic change of proximal tubule were observed following treatment with DEHA. It has been reported that repeated dosing of peroxisome proliferators including DEHA induced hypertrophic changes of the liver and kidney, which was characterized by increases in the number of peroxisomes (Holden et al., 1999) . Eosinophilic change of proximal tubule was observed in previous repeated dose toxicity studies of DEHA (Miyata et al., 2006) and DEHP (David et al -ered attributable to the PPAR activation.
In the female fertility study, staining around perineum was observed in the 1,000 mg/kg and above groups, and a before mating period was observed in the 2,000 mg/kg group compared with the control group. As for the effects in mean estrus cycle length was observed in the 1,000 mg/kg and above groups, and a significant decrease in implantation rate was observed in the 2,000 mg/kg group compared with the control group. As for the effects on early embryonic development, a significant increase in post-implantation loss rate was observed in the 1,000 mg/ -tation loss were observed in the 2,000 mg/kg group compared with the control group. Increase in atresia of large follicle, decrease in newly formed corpus luteum and follicular cyst observed in the repeated dose toxicity studies, suggesting that DEHA disturbed ovulation, were correlated with the result that DEHA affected the estrus cycle in the female fertility study. As for the relationship of these in pre-implantation loss rate and post-implantation loss rate and decrease in implantation rate and number of live embryos, more detailed studies are needed. Howevobserved in the fertility study with DEHP, which possesses PPAR-alpha activity (Giuseppe et al -ings may be mediated by PPAR-alpha activity of DEHA (Motojima et al., 1998) . From these results, the NOAEL for general toxicity in dams, for reproductive functions of dam, and for early embryonic development were considered to be 200 mg/kg.
In the present study, evaluation of the ovaries was carried out in accordance with the method proposed by the Japan Pharmaceutical Manufacturers Association. Halving transversally ovaries to observe maximum area of the ovary at dissection in preparing the histopathological specimens made it possible to examine as many follicles and corpus luteum as possible. Immunohistochemical stain using anti-PCNA antibody -tion and detection of atresia of follicle easier. Classifying Vol. 34 Special Issue I SP108 possible to evaluate the toxicity at varying stages of follicular growth. Furthermore, performing the estrus cycle observation in the repeated dose toxicity study made it possible to evaluate ovarian toxicities taking into account estrus cyclicity.
In conclusion, a 2-week administration period is sufficient for detection of the ovarian toxicities following treatment with DEHA by new histopathological examination of the ovaries. Furthermore, ovarian pathological parameters regarding the reproductive functions and early embryonic development in the female fertility study since the lowest observed adverse effect level (LOAEL) focused on ovary in the repeated dose toxicity study was same as the LOAEL in the female fertility study.
